Travere Therapeutics (TVTX) Tops Q4 EPS by 212c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- S&P 500 up, Nasdaq at record high as megacap tech stocks rise
- Oil slips on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts TVTX Hot Sheet
Join SI Premium – FREE
Travere Therapeutics (NASDAQ: TVTX) reported Q4 EPS of $0.94, $2.12 better than the analyst estimate of ($1.18). Revenue for the quarter came in at $45.05 million versus the consensus estimate of $41.68 million.
For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alethia Capital Starts TTM Technologies (TTMI) at Overweight, 'A Unique Proxy Standing for USA PCB'
- RXO shares soar as C.H. Robinson announces $5.8B cash and stock buyout
- S&P Global (SPGI) PT Lowered to $531 at Mizuho
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
